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Abstract
Multiple sclerosis (MS) is a debilitating, chronic demyelinating disease of the central nervous system affecting over 2 million
people worldwide. The TAM family of receptor tyrosine kinases (TYRO3, AXL and MERTK) have been implicated as important
players during demyelination in both animal models of MS and in the human disease. We therefore conducted an
association study to identify single nucleotide polymorphisms (SNPs) within genes encoding the TAM receptors and their
ligands associated with MS. Analysis of genotype data from a genome-wide association study which consisted of 1618 MS
cases and 3413 healthy controls conducted by the Australia and New Zealand Multiple Sclerosis Genetics Consortium
(ANZgene) revealed several SNPs within the MERTK gene (Chromosome 2q14.1, Accession Number NG_011607.1) that
showed suggestive association with MS. We therefore interrogated 28 SNPs in MERTK in an independent replication cohort
of 1140 MS cases and 1140 healthy controls. We found 12 SNPs that replicated, with 7 SNPs showing p-values of less than
1025 when the discovery and replication cohorts were combined. All 12 replicated SNPs were in strong linkage
disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS
susceptibility.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating and
inflammatory disease of the central nervous system (CNS),
affecting mainly individuals of European ancestry [1]. The disease
is characterised by CNS demyelination, loss of oligodendrocytes,
inflammation, as well as neurodegeneration. Susceptibility to MS
is thought to involve a complex interplay of genetic and
environmental factors, with the HLA-DRB1*1501-DQBI*602
(HLA-DR15) haplotype in the major histocompatibility complex
(MHC) being the predominant genetic risk factor [2,3]. Other
genetic associations have been observed and replicated in IL7R
[2], IL2RA [2], CLEC16A [4,5], CD226 [5], CD6 [6], IRF8 [6],
TNFRSF1A [6], STAT3 [7], KIF21B [8], TMEM39A [8] and TYK2
[9].
The TAM receptors (TYRO3, AXL and MERTK) comprise a
family of structurally related receptor tyrosine kinases that have
two identified ligands: GAS6 and protein S [10,11,12]. TAM
receptor signaling has been implicated in several biological
processes, including cell survival and proliferation [13,14,15,16],
immune regulation [17,18,19] and phagocytosis of apoptotic cells
[19,20,21]. As these are all key processes involved in demyelin-
ation, several recent studies have examined the role of these
receptors in animal models of MS, as well as in the human disease.
Previous work in our laboratory examined the course of
cuprizone-induced demyelination in mice lacking the TAM
receptor ligand GAS6. Cuprizone is a neurotoxin that when
incorporated into the feed of mice, induces specific and focal T
cell-independent demyelination within the CNS, particularly in
the corpus callosum [22,23,24]. Following 3 weeks of cuprizone-
challenge we observed greater demyelination, which corresponded
with increased oligodendrocyte loss and microglial activation in
the absence of GAS6 compared with wild-type mice [25]. In a
separate study, AXL receptor knockout mice displayed an overall
reduction in myelination following 6 weeks of cuprizone-challenge,
as well as a delay in microglial activation and the clearance of
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myelin debris and apoptotic cells [26]. The apparent differences
between the phenotypes of the ligand and single receptor knockout
mice during cuprizone-challenge highlights the complexity of
TAM receptor signaling, but more importantly, these studies
clearly show that loss of TAM receptor signaling is accompanied
by increased demyelination in the cuprizone model.
The studies by Binder et al. [25] and Hoehn et al. [26] have
focused on experimental animals, but a recent study has
implicated the TAM receptors as important players in human
MS as well. In a study of human MS lesions, levels of soluble forms
of the TAM receptors, which can act as decoy receptors for the
membrane-bound receptors, were compared in chronic silent MS
lesions, chronic active MS lesions and healthy controls. It was
found that levels of soluble AXL were higher in chronic silent
lesions, while levels of soluble MERTK were higher in chronic
active lesions compared with controls [27]. These elevated levels of
soluble AXL and MERTK also correlated with low levels of GAS6
within the lesions [27], suggesting that loss of TAM receptor
signaling may prolong MS lesion activity. Taken together, these
studies implicate TAM receptor signaling as playing a key role in
several processes affecting the outcome of demyelination in both
animal models as well as human MS.
Given the aforementioned results, we hypothesized that polymor-
phisms in the TAM receptor or ligand genes would be associated with
MS and thus also be involved in the aetiology of the disease. In a
recent genome-wide association study (GWAS) conducted by the
Australian and New ZealandMultiple Sclerosis Genetics Consortium
(ANZgene) [28], several single nucleotide polymorphisms (SNPs)
within the MERTK gene (Chromosome 2q14.1, Accession Number
NG_011607.1) showed suggestive association with susceptibility to
MS, while SNPs within theTYRO3, AXL, GAS6 and PROS1 genes did
not show any suggestive associations. We therefore conducted a
replication study with a candidate gene approach to validate this
finding by genotyping 28 common SNPs within MERTK in an
independent cohort of 1140 MS cases and 1140 healthy controls. In
this study, we identify 12 replicated SNPs that are significantly
associated with MS susceptibility, suggesting the MERTK gene as a
novel risk gene involved in MS susceptibility.
Methods
Study subjects
The Melbourne Health Human Research Ethics Committee
and the Australian Bone Marrow Donor Registry Ethics
Committee granted approval for this research. Written consent
was given by the subjects for their information to be stored in the
study database and used for research.
Genotype data from a GWAS conducted by the ANZgene
Consortium [28] was used as a discovery dataset to search the five
TAM receptor and ligand genes for SNPs that showed suggestive
association with MS susceptibility. Following quality control as
outlined in the ANZgene GWAS [28], this dataset consisted of
1618 MS cases of European ancestry from Australia and New
Zealand, and 3413 healthy controls of European ancestry from
Australia, the UK and the US. All GWAS subjects were genotyped
using Illumina arrays (Illumina, California, USA) [28].
A sample of 1140 MS cases and 1140 healthy controls from
Australia and New Zealand were used as a replication cohort in
this study (Table 1). Australian MS cases were volunteers recruited
from Adelaide, Brisbane, Gold Coast, Hobart, Melbourne,
Newcastle, Perth and Sydney. MS cases from New Zealand were
recruited through a national prevalence survey. All cases had
definite, clinically definite, or laboratory-supported definite MS
according to the McDonald and Poser criteria, respectively. All
controls were from the Australian Bone Marrow Donor Registry
with no history of clinically isolated syndrome or MS at the time of
collection. All samples were obtained from individuals of
European ancestry from Australia and New Zealand.
SNP selection
Of the top 7 directly genotyped SNPs in TAM receptor and
ligand genes in the ANZgene GWAS, 6 were in the MERTK gene
(Table S1). We therefore took a candidate gene approach focusing
on MERTK. Using the total of 22 directly genotyped SNPs in the
MERTK gene as proxies, non-genotyped SNPs that were tagged in
the GWAS dataset were imputed using Beagle (see below). Based
on this information, we selected 28 SNPs that showed suggestive
association with MS to interrogate in the replication phase. These
included the top 6 genotyped SNPs in the ANZgene GWAS, plus
22 imputed SNPs that showed suggestive association with MS.
Genotyping
Subjects in the replication cohort were genotyped using the
Sequenom MassARRAY system and iPLEX Gold chemistry
under conditions recommended by the manufacturer (Sequenom,
California, USA). Genomic DNA from all subjects was extracted
as described in the ANZgene GWAS [28].
Imputation
Imputation of tagged, un-genotyped SNPs in the GWAS cohort
was performed with Beagle v3.2.0 (http://faculty.washington.edu/
browning/beagle/beagle.html) [29] using the default settings.
Analyses were performed to impute the most likely values of
missing genotypes, and to calculate posterior genotype probabil-
ities at all HapMap SNPs. To do this, data from unphased
Hapmap phase II CEU (USA residents of northern and western
European ancestry) individuals (release 24, build 36, forward
strand) was used as a reference panel.
Statistical analysis
For SNPs that were genotyped in both the GWAS and
replication cohorts, association analysis was performed using the
Table 1. Replication sample data.
MS patients (n=1140) Controls (n=1140)
Mean age of onset ±
standard deviation1:
33.85610.14 N/A
Sex:
Female 816 669
Male 247 450
Unknown 77 21
MS disease course: N/A
RRMS 632
SPMS 369
PPMS 58
Single 1
Unknown 80
MS: multiple sclerosis; N/A: not applicable; RRMS: relapsing-remitting multiple
sclerosis; SPMS: secondary-progressive multiple sclerosis; PPMS:
primary-progressive multiple sclerosis; Single: first demyelinating event.
1Age information only available for 1069 MS patients and the mean is
calculated as such.
doi:10.1371/journal.pone.0016964.t001
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–assoc command in PLINK v1.07 (http://pngu.mgh.harvard.
edu/,purcell/plink/) [30].
For SNPs that were imputed in either the GWAS or
replication subjects, posterior allele dosages were used to
perform the association analysis. The posterior allele dosage is
twice the posterior genotype probability of the AA genotype
plus the posterior genotype probability of the AB genotype
(where A represents one of the alleles for the marker and B the
other allele). Linear regression of allele dosages on case-control
status was performed to test for association, with adjustment
for sample group (discovery/replication) in the combined
dataset.
Linkage disequilibrium analysis
To investigate linkage disequilibrium (LD) between SNPs, data
from Hapmap phase II CEU individuals (release 24, build 36,
forward strand) was analysed using Haploview v4.2 (http://www.
broadinstitute.org/haploview) [31].
Figure 1. Location of SNPs within the MERTK gene. A. Schematic of the MERTK gene (Accession Number NG_011607.1, Chromosome 2:
12,656,056-112,787,138 forward strand). Black rectangles indicate the 19 exons of MERTK and grey lines show physical location of the 12 replicated
SNPs. B. Linkage disequilibrium (LD) structure for all Hapmap phase II CEU SNPs (release 24, build 36, forward strand) in the MERTK gene, visualized
using Haploview v4.2 (ref. 29). Lines point out the 12 replicated SNPs. Inter-SNP LD is represented by shaded squares, with red shading indicating
strongest LD (D9=1), and white indicating weak or no LD between SNPs.
doi:10.1371/journal.pone.0016964.g001
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Hardy-Weinberg equilibrium analysis
Hardy-Weinberg equilibrium of SNPs was determined by using
the –hardy command in PLINK v1.07. SNPs in significant Hardy-
Weinberg disequilibrium (p,1027) in control groups were
excluded from further analysis.
Results and Discussion
Our discovery dataset consisted of genotype data of 1618 MS
cases and 3413 controls of European ancestry from a recent
GWAS [28]. Of the top 7 directly genotyped SNPs in genes
encoding TAM receptors and their ligands that showed suggestive
p-values for association with MS in the discovery dataset, 6 were in
the MERTK gene (Chromosome 2q14.1, Accession Number
NG_011607.1) (Table S1). Based on association analysis of
directly genotyped and imputed SNPs in the discovery dataset,
we conducted a replication study with a candidate gene approach
focusing on 28 SNPs within the MERTK gene. In our independent
replication cohort, 12 of the 28 interrogated SNPs replicated, with
association p-values of less than 0.05 and odds ratios going in the
same direction as in the discovery dataset (Fig. 1A, Table 2). All 12
replicated SNPs had p-values of less than 10-4 when the discovery
and replication cohorts were combined. Notable SNPs with
combined p-values of less than 1025 were rs867311, rs12477716,
rs17835605, rs4278932, rs4528767, rs17174870 and rs1516629.
Linkage disequilibrium analysis showed all 12 replicated SNPs to
be in strong LD with each other, with D9=1 and r2.0.95 for all
pairs of SNPs (Fig. 1B).
We included the top 6 genotyped SNPs from the discovery
dataset with p-values of less than 0.05 in the 28 SNPs that were
genotyped in our replication cohort. Of these SNPs, only
rs11884641 replicated, with the other 5 showing p-values of
greater than 0.05 in the replication cohort (Table 2).
Although the SNPs interrogated in this study do not reach the
level of genome-wide significance (p,561028), our study
nevertheless identifies 12 SNPs that replicate in two independent
cohorts of MS cases and controls, and that reach a level of
significance required for a candidate gene approach. This provides
strong evidence that the MERTK gene is associated with MS
susceptibility. The 12 replicated SNPs are all common variants;
although all are intronic and in strong LD with each other, they
may be tagging potentially rare causal variants within coding
regions of the gene. Fine mapping of the MERTK gene and
interrogation of different populations with larger sample sizes may
aid in determining the exact causal variants. As MS is a genetically
complex disease, the MERTK gene may also represent one of
many disease loci that confer susceptibility to MS when present in
combination.
The TAM receptors have been shown to be major players in
regulation of the immune response [17,18,19]. Triple TAM
receptor mutants develop widespread autoimmunity, with in-
creased circulating levels of autoantibodies [17]. The autoimmu-
nity phenotype showed a gene dosage effect, with less severe
autoimmunity in mice deficient for two TAM receptors, and an
even milder, although still pronounced effect in mice deficient for
just one TAM receptor [17]. The role of MERTK in regulating
the immune response has been extensively examined, especially in
relation to its role in the phagocytosis of apoptotic cells. It has been
shown that MERTK knockout mice have macrophages deficient
in their ability to clear apoptotic cells, leading to the development
of a progressive systemic lupus erythematosus-like phenotype
[20,32]. In the immune system, MERTK has also been implicated
in regulation of dendritic cell activation [33], T cell selection and
tolerance [34,35], and B cell homeostasis and tolerance [36,37].
Multiple sclerosis has often been classified as an autoimmune
disease, and the obvious inflammatory response observed in the
disease strongly supports this hypothesis. In light of previous
studies implicating the TAM receptors in regulating both
demyelination and autoimmune responses in both experimental
animals and human MS lesions (for review, see ref. [38]), the
present study provides strong evidence that MERTK represents a
genuine MS susceptibility gene.
In conclusion, this candidate gene study has identified an
association of MS with 12 SNPs in the MERTK gene that
replicated in two independent cohorts of MS cases and controls,
an association that is particularly compelling given the previous
studies implicating TAM receptor signalling in demyelination and
autoimmunity. Further fine mapping studies will be required to
determine the causal variant or variants.
Supporting Information
Table S1 SNP associations of all directly genotyped TAM
receptor and ligand genes in the top 300,000 SNPs of the
discovery (GWAS) dataset.
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